Search company, investor...

Lytix Biopharma

Founded Year



Other Investors | Alive

About Lytix Biopharma

Pre clinical developer of lytic peptide drugs for the treatment of resistant bacterial, fungal infections and tumor progression, closed a $10.4M Series D financing. oncology

Headquarters Location

Tromso Research Park Tromsø


Missing: Lytix Biopharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Lytix Biopharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Lytix Biopharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lytix Biopharma is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Lytix Biopharma Patents

Lytix Biopharma has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Oncology
  • Bullying
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immunology, Immune system, Cancer treatments, Monoclonal antibodies


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immunology, Immune system, Cancer treatments, Monoclonal antibodies



Latest Lytix Biopharma News

Lytix Biopharma third quarter 2022 results

Nov 17, 2022

News provided by Share this article Share this article OSLO, Norway, Nov. 17, 2022 /PRNewswire/ -- Lytix Biopharma ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immune-oncology company, today releases its third quarter 2022 results. Highlights include regulatory approval received to expand our ATLAS-IT-05 study to three European countries and the appointment of Stephen Worsley as CBO. "We are very pleased to now being able to include patients from Spain, France and Norway in our Phase II study. The expansion of the site network will mitigate recruitment challenges, drive enrollment towards completion and extend the clinical impact field for LTX-315", says CEO and Co-founder of Lytix Biopharma, Øystein Rekdal. Highlights from the third quarter 2022: LTX-315         Regulatory approval received to expand the ATLAS-IT-05 study to three European countries (Norway, France and Spain) Verrica Pharmaceuticals is in good progress with their Phase II study in BCC, and the conclusion of part 1 of three parts is expected in Q1 2023 IND enabling activities required to start a Phase I study with LTX-401 is progressing as planned Stephen Worsley appointed as Chief Business Officer (CBO), and he is already introducing Lytix to KOLs and companies within the industry Post-period events: Compelling data describing how LTX-315 activates dendritic cells and contributes to anti-cancer immune response was presented at the Society for Immunotherapy of Cancer (SITC) Additional study sites opened in Europe to support ATLAS-IT-05 patient recruitment ATLAS-IT-04 Clinical Study Report completed Proof-of-concept achieved, demonstrating the clinical benefits of LTX-315 in combination with Adoptive Cell Therapy (ACT) in heavily pre-treated sarcoma patients Financial: Total operating income for Q3 2022 includes NOK 1.4 million in revenue from our licensing partner Verrica. This revenue is for sale of LTX-315 for use in Verrica's development program. This is the first, and currently only, agreement where Lytix sells LTX-315 to a commercial party. Total operating expenses for the six months that ended September 30 are in line with the same period last year, and as a clinical drug development company, R&D efforts represent the majority of our expenses. A portion of the excess liquidity has been placed in a liquidity fund explaining the increase in short-term financial investments. At the end of the period cash plus short-term financial investments was NOK 172 million. Key figures (unaudited):   Government grants recognized in profit and loss, part of Other operating Income, for Q2 2022 was reported at NOK 805 thousand which was NOK 750 thousand lower than actual. The correct amount is NOK 1,555 thousand. The figures in this report are correct, but the YTD figures will therefore not be reconcilable with the H1 report without adjusting for this error. The results will be presented in a webcast with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein today at 14.30 CEST. The presentation and subsequent Q&A session will be held in English and may be viewed live at A recording of the presentation will be made available on after the presentation. For more information, please contact: Gjest Breistein,

Lytix Biopharma Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lytix Biopharma Rank

Lytix Biopharma Frequently Asked Questions (FAQ)

  • When was Lytix Biopharma founded?

    Lytix Biopharma was founded in 2003.

  • What is Lytix Biopharma's latest funding round?

    Lytix Biopharma's latest funding round is Other Investors.

  • Who are the investors of Lytix Biopharma?

    Investors of Lytix Biopharma include Sakorn Invest Nord and NorInnova.

  • Who are Lytix Biopharma's competitors?

    Competitors of Lytix Biopharma include Reata Pharmaceuticals, Intarcia Therapeutics, PrevaCept Infection Control, InterMune, Affinium Pharmaceuticals and 11 more.

Compare Lytix Biopharma to Competitors

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Topica Logo

Topica provides marketing and sales solutions for businesses with online channels. Topica's solution enables businesses and organizations world-wide to find new prospective customers and sell more online. Using Topica, online marketers better leverage their current marketing initiatives, such as paid search, affiliate programs and display advertising, as they turn more traffic into first-time buyers and loyal long term customers.

Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

Koronis Pharmaceuticals

Koronis Pharma develops antiviral therapeutics based on Viral Decay Acceleration, which exploits the strength of a virus to target its collapse.


Lifepharms is researching natural products for medicinal and agricultural uses, including anticancer and pox virus medications.

Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.